Lack of Prognostic Significance of C-erbB-2 Expression in Low- and High- grade Astrocytomas |
Muallaoglu, Sadik
(Department of Medical Oncology, Faculty of Medicine, University of Baskent)
Besen, Ali Ayberk (Department of Medical Oncology, Van Training and Research Hospital) Ata, Alper (Department of Medical Oncology, Mersin State Hospital) Mertsoylu, Huseyin (Department of Medical Oncology, Faculty of Medicine, University of Baskent) Arican, Ali (Department of Medical Oncology, Faculty of Medicine, University of Mersin) Kayaselcuk, Fazilet (Department of Pathology, Faculty of Medicine, University of Baskent) Ozyilkan, Ozgur (Department of Medical Oncology, Faculty of Medicine, University of Baskent) |
1 | Rainov NG, Dobberstein KU, Bahn H, et al (2007). Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol, 35, 13-28. |
2 | Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP (2011). Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg, 66, 10-17. DOI ScienceOn |
3 | Yaziji H, Goldstein LC, Barry TS, et al (2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 291, 1972-77. DOI ScienceOn |
4 | Pfeiffer D, Stellwag B, Pfeiffer A, et al (1989). Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol, 33, 146-50. DOI ScienceOn |
5 | Pigott TJ, Robson DK, Palmer J, Ward LM (1993). Expression of epidermal growth factor receptor in human glioblastoma multiforme. Br J Neurosurg, 7, 261-5. DOI |
6 | Potti A, Forseen SE, Koka VK, et al (2004). Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest, 22, 537-44. DOI ScienceOn |
7 | Reszec J, Bernaczyk PS, Milewski R, Chyczewski L, Mariak Z (2011). C-erbB-2 protein expression in astrocytic tumors of the brain. Med Sci Monit, 17, 216-20. |
8 | Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1, 1398-402. |
9 | Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. DOI ScienceOn |
10 | Stummer W, Reulen HJ, Meinel T, et al (2008). ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery, 62, 564-76. DOI ScienceOn |
11 | Torp SH, Gulati S, Johannessen E, Dalen A (2007). Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res, 26, 353-9. |
12 | Koka V, Potti A, Forseen SE, et al (2003). Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol, 26, 332-5. |
13 | Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr (2002). HER2/neu expression in malignant lung tumors. Semin Oncol, 29, 51-8. |
14 | Haynik DM, Roma AA, Prayson RA (2007). HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol, 15, 56-8. DOI ScienceOn |
15 | Jakola AS, Myrmel KS, Kloster R, et al (2012). Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA, 308, 1881-8. DOI |
16 | Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109. DOI ScienceOn |
17 | Ozawa S, Ueda M, Ando N, Shimizu N, Abe O (1989). Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer, 63, 2169-73. DOI |
18 | Mineo JF, Bordron A, Baroncini M, et al (2007). Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol, 85, 281-7. DOI |
19 | Mineo JF, Quintin-Roue I, Lucas B, Buburusan V, Besson G (2002). Glioblastomas: clinical study and search for prognostic factors. Neurochirurgie, 48, 500-9. |
20 | Neal DE, Marsh C, Bennett MK, et al (1985). Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet, 1, 366-8. |
21 | Gulati S, Jakola AS, Johannesen TB, Solheim O (2012). Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg, 78, 518-26. DOI |
22 | Albarello L, Pecciarini L, Doglioni C (2011). HER2 testing in gastric cancer. Adv Anat Pathol, 18, 53-9. DOI ScienceOn |
23 | Bauknecht T, Kohler M, Janz I, Pfleiderer A (1989). The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer: EGF receptors and factors in gynecological carcinomas. J Cancer Res Clin Oncol, 115, 193-9. DOI |
24 | Gehan EA, Walker MD (1997). Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr, 46,189-95. |
25 | Gulati S, Jakola AS, Nerland US, Weber C, Solheim O (2011). The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg, 76, 572-79. DOI |
26 | Haapasalo H, Hyytinen E, Sallinen P, et al (1996). c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer, 73, 620-3. DOI |
27 | Lacroix M, Abi-Said D, Fourney DR, et al (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg, 95, 190-8. DOI |
28 | Hiesiger EM, Hayes RL, Pierz DM, Budzilovich GN (1993). Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol, 16, 93-104. DOI ScienceOn |